Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 78Carcinoma, Non-Small-Cell Lung 43Nasopharyngeal Carcinoma 24Lung Neoplasms 23Breast Neoplasms 14Cholangiocarcinoma 13Lymphoma, Large B-Cell, Diffuse 12Neoplasm Metastasis 11Ovarian Neoplasms 10Lymphoma, Extranodal NK-T-Cell 10Recurrence 9Biliary Tract Neoplasms 9Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Nasopharyngeal Neoplasms 6Lymphoma 6Lymphoma, T-Cell, Peripheral 5Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rectal Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Gallbladder Neoplasms 4Colonic Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma of Lung 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell 3

Interventions

margetuximab 1apatinib 1Vinorelbine 1Trastuzumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Cancer Metastatic × Gemcitabine × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡